Cefazolin

Due to E. coli, P. mirabilis, Klebsiella  species and some strains of enterobacter and enterococci. 

Due to S. aureus (pennicillin-sensitive and penicillin resistant), S. pyogenes, and other strains of streptococci.

Due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species and Staphylococcus aureus.  

Due to S. aureus.

(i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species and some strains of enterococci.

Due to S. pneumoniae, S. aureus (pennicillin-sensitive and penicillin resistant) P. mirabilis, E. coli, and Klebsiella species

Due to S. aureus (pennicillin-sensitive and penicillin resistant), and group A beta hemolytic streptococci. 

Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin.

The prophylactic administration of cefazolin preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones).

The perioperative use of cefazolin may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty).

The prophylactic administration of cefazolin should usually be discontinued within a 24-hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of cefazolin may be continued for 3 to 5 days following the completion of surgery.

If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted. (See DOSAGE AND ADMINISTRATION)

Prolonged use of cefazolin may result in the overgrowth of nonsusceptible organisms. Careful clinical observation of the patient is essential.

Prescribing Cefazolin for Injection, USP is the absence of a proven or strongly suspected bacterial infection of a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

When cefazolin is administered to patients with low urinary output because of impaired renal function, lower daily dosage is required (see DOSAGE AND ADMINISTRATION).

As with other beta-lactam antibiotics, seizures may occur if inappropriately high doses are administered to patients with impaired renal function (see DOSAGE AND ADMINISTRATION).

Cefazolin Injection, USP, as with all cephalosporins, should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.

Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.

A false positive reaction for glucose in the urine may occur with Benedict’s solution, Fehling’s solution or with CLINITEST® tablets, but not with enzyme-based tests such as CLINISTIX®.

Positive direct and indirect antiglobulin (Coombs) tests have occurred; these may also occur in neonates whose mothers received cephalosporins before delivery.

Mutagenicity studies and long-term studies in animals to determine the carcinogenic potential of cefazolin have not been performed.